These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23565772)

  • 1. Retrospective assessment of secondary prophylaxis for invasive aspergillosis in neutropenic hematology patients and identification of risk factors for relapse of fungal disease.
    Kikuchi M; Nakasone H; Mitani K; Gotoh M; Kobayashi A; Kurita N; Saito T; Sato K; Kanda Y;
    Scand J Infect Dis; 2013 Jul; 45(7):531-6. PubMed ID: 23565772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study.
    Rubio PM; Sevilla J; González-Vicent M; Lassaletta A; Cuenca-Estrella M; Díaz MA; Riesco S; Madero L
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):642-6. PubMed ID: 19684521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive aspergillosis in a tertiary-care hospital in Thailand.
    Kiertiburanakul S; Thibbadee C; Santanirand P
    J Med Assoc Thai; 2007 May; 90(5):895-902. PubMed ID: 17596043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome.
    van de Peppel RJ; Dekkers OM; von dem Borne PA; de Boer MG
    Med Mycol; 2014 Oct; 52(7):699-705. PubMed ID: 25049037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
    Herbrecht R; Patterson TF; Slavin MA; Marchetti O; Maertens J; Johnson EM; Schlamm HT; Donnelly JP; Pappas PG
    Clin Infect Dis; 2015 Mar; 60(5):713-20. PubMed ID: 25414266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients.
    Oshima K; Kanda Y; Asano-Mori Y; Nishimoto N; Arai S; Nagai S; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    J Antimicrob Chemother; 2007 Aug; 60(2):350-5. PubMed ID: 17584800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy.
    Hoenigl M; Seeber K; Koidl C; Buzina W; Wölfler A; Duettmann W; Wagner J; Strenger V; Krause R
    Mycoses; 2013 Jul; 56(4):471-6. PubMed ID: 23432536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outbreak of invasive aspergillosis in heart transplant recipients: The role of screening computed tomography scans in asymptomatic patients and universal antifungal prophylaxis.
    Kabbani D; Goldraich L; Ross H; Rotstein C; Husain S
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis.
    Hadrich I; Makni F; Cheikhrouhou F; Neji S; Amouri I; Sellami H; Trabelsi H; Bellaaj H; Elloumi M; Ayadi A
    Pathol Biol (Paris); 2012 Dec; 60(6):357-61. PubMed ID: 22154334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-nine cases of invasive aspergillosis in neutropenic patients.
    Saghrouni F; Ben Youssef Y; Gheith S; Bouabid Z; Ben Abdeljelil J; Khammari I; Fathallah A; Khlif A; Ben Saïd M
    Med Mal Infect; 2011 Dec; 41(12):657-62. PubMed ID: 22036518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole].
    Mattner F; Chaberny IF; Weissbrodt H; Fischer S; Gastmeier P; Haubitz B; Gottlieb J; Mattner L; Strueber M
    Mycoses; 2005; 48 Suppl 1():51-5. PubMed ID: 15826288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
    Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
    J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis.
    Cordonnier C; Botterel F; Ben Amor R; Pautas C; Maury S; Kuentz M; Hicheri Y; Bastuji-Garin S; Bretagne S
    Clin Microbiol Infect; 2009 Jan; 15(1):81-6. PubMed ID: 19154482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive aspergillosis in a paediatric haematology department: a 15-year review.
    Crassard N; Hadden H; Piens MA; Pondarré C; Hadden R; Galambrun C; Pracros JP; Souillet G; Basset T; Berthier JC; Philippe N; Bertrand Y
    Mycoses; 2008 Mar; 51(2):109-16. PubMed ID: 18254746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients.
    Fernandez-Gerlinger MP; Jannot AS; Rigaudeau S; Lambert J; Eloy O; Mignon F; Farhat H; Castaigne S; Merrer J; Rousselot P
    Infect Control Hosp Epidemiol; 2016 Jul; 37(7):845-51. PubMed ID: 27340735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases.
    Miyakoshi S; Kusumi E; Matsumura T; Hori A; Murashige N; Hamaki T; Yuji K; Uchida N; Masuoka K; Wake A; Kanda Y; Kami M; Tanaka Y; Taniguchi S
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):771-7. PubMed ID: 17580255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of aspergillosis in non-neutropenic patients in Swiss teaching hospitals.
    Garbino J; Fluckiger U; Elzi L; Imhof A; Bille J; Zimmerli S
    Clin Microbiol Infect; 2011 Sep; 17(9):1366-71. PubMed ID: 20950331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.